Related Experiment Video
Updated: Dec 20, 2025
Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
Published on: April 7, 2023
Guideline No. 398: Progesterone for Prevention of Spontaneous Preterm Birth
Venu Jain1, Sarah D McDonald2, William R Mundle3
1Edmonton, AB.
Objectives:
To assess the benefits and risks of progesterone therapy for women at increased risk of spontaneous preterm birth (SPB) and to make recommendations for the use of progesterone to reduce the risk of SPB and improve postnatal outcomes.
Options:
To administer or withhold progesterone therapy for women deemed to be at high risk of SPB.
Outcomes:
Preterm birth, neonatal morbidity and mortality, and postnatal outcomes including neurodevelopmental outcomes.
Intended Users:
Maternity care providers, including midwives, family physicians, and obstetricians.
Target Population:
Pregnant women at increased risk of SPB.
Evidence:
Medline, PubMed, EMBASE, and the Cochrane Library were searched from inception to October 2018 for medical subject heading (MeSH) terms and keywords related to pregnancy, preterm birth, previous preterm birth, short cervix, uterine anomalies, cervical conization, neonatal morbidity and mortality, and postnatal outcomes. This document represents an abstraction of the evidence rather than a methodological review.
Validation Methods:
This guideline was reviewed by the Maternal-Fetal Medicine Committee of the Society of Obstetricians and Gynaecologists of Canada (SOGC) and approved by the SOGC Board of Directors.
Benefits, Harms, And/Or Costs:
Therapy with progesterone significantly reduces the risk of SPB in a subpopulation of women at increased risk. Although this therapy entails a cost to the woman in addition to the discomfort associated with its use, no other adverse effects to the mother or the baby have been identified.
Summary Statements (Grade Ratings In Parentheses):
RECOMMENDATIONS (GRADE RATINGS IN PARENTHESES).
More Related Videos
14:43A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
Published on: January 12, 2018
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Related Concept Videos
01:07Teratogenicity
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:27Ovarian Cycle
01:22Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
01:24Gonadal and Placental Hormones
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...